What's Happening?
Bruntwood SciTech, a joint venture between Bruntwood, L&G, and Greater Manchester Pension Fund, has announced a significant lease agreement with Cellular Origins for the Da Vinci Building at Melbourn Science Park in Cambridge. Cellular Origins, a leader
in automated cell therapy manufacturing, will establish its new global headquarters in the 41,000 sq ft space. This move follows the company's Series A funding and rapid growth. The new location, previously occupied by AstraZeneca, places Cellular Origins in the UK's R&D 'Golden Triangle', providing access to world-class research and talent. The company aims to industrialize cell therapy manufacturing by combining mobile robotics, automation, and AI with proven bioprocess technologies.
Why It's Important?
The establishment of Cellular Origins' headquarters at Melbourn Science Park marks a significant step in scaling up cell therapy manufacturing, which is crucial for meeting growing patient demand. The high cost of manufacturing has been a barrier to the widespread adoption of cell therapies, but Cellular Origins' approach could reduce these costs and make treatments more accessible. The move also highlights the importance of strategic locations like the 'Golden Triangle' in fostering innovation and collaboration in the life sciences sector. By expanding its operations, Cellular Origins is poised to enhance its collaboration with global partners and contribute to the advancement of cell therapy technologies.
What's Next?
Cellular Origins plans to double its workforce and further develop its automated manufacturing platform, Constellation, at the new facility. The company will focus on delivering commercial-scale cell therapy manufacturing systems to customers, potentially transforming the industry. As part of the Bruntwood SciTech community, Cellular Origins will benefit from access to a network of over 1,450 innovation-focused companies and strategic partnerships with universities and research institutions. This environment is expected to support the company's growth and innovation efforts, positioning it as a leader in the field of advanced therapies and life sciences.
